KMTS logo

KESTRA MEDICAL TECHNOLOGIES

KMTSNASDAQ
πŸ† #1993 by market capEarnings Dec 11US Equity
$29.88β–Ό $0.10 (βˆ’0.32%)
Pre-market Β· at close
πŸ””
Track KMTS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–² 5.6%
14dβ–² 4.3%
30dβ–² 5.0%
ytdβ–² 12.6%
1yβ–² 7.0%
🏦Market Cap
$1.78B
Small Cap
πŸ“ˆRevenue Growth (YoY)
60.7%
High Growth
πŸ“ŠGross Margin
53.9%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
16.7x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$29.51 – $31.00
52-Week Range
$17.34 – $30.42
Volume (shares)
41,621
Avg Volume (shares)
β€”
Shares Outstanding
59.6M
Next Earnings
2026-12-11

Fundamentals Snapshot

Annual Revenue
$95M
Last Q Revenue
$31M
P/E Ratio
β€”
P/S Ratio
16.7x
EPS (TTM)
$-2.67
Dividend Yield
β€”
Dilution (1yr)
+14.0%
KMTS logo

KESTRA MEDICAL TECHNOLOGIES

KMTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$95Mβ–² +59.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.4%β–² +26.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$135Mβ–² +26.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$117Mβ–² +15.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.6Mβ–² +14.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$8Mβ–Ό βˆ’$139M YoY
StockOtter Β· stockotter.space

About KESTRA MEDICAL TECHNOLOGIES

Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
14 analysts
Strong Buy6
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.